Transcutaneous Auricular Vagus Nerve Stimulation for Persistent Post-concussion Symptoms
Key facts
- Who runs it
- University of Liege
- Where
- Belgium1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 48 people, planned
- Started
- 28 May 2025
- Expected to end
- Jun 2027
- Type of study
- Interventional, 2 groupsOne group gets a sham (pretend) treatment, for comparison.
- Treatments tested
- Active taVNS
- Sham taVNS
- Record updated
- 12 June 2025
Who can take part
- Age
- 18 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (9)Hide the full registry criteria
Who can take part
- Age between 18 and 65
- Between 4 weeks and 1-year post-diagnosis of a concussion
- Score equal or above 16 on the Rivermead Post-Concussion Questionnaire
- Intact skin at the electrode site
Who cannot take part
- Presence of an active implant (e.g., pacemaker, cochlear implant)
- Excessive alcohol consumption (> 14 drinks per week) and/or drug (> 1x/week) use within the past 6 months
- History of chronic neurological or psychological disorders (still untreated 6 months preceding inclusion)
- History of myocardial infarction or cardiac arrhythmia
- Pregnancy or breastfeeding
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Persistent post-concussive symptoms
This trial is currently available in Belgium.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Persistent post-concussive symptoms (PPCS) affect a significant proportion of individuals following a concussion, leading to debilitating impacts on their quality of life and work capacity. Currently, effective treatments for PPCS are limited, despite their lasting and debilitating impact. Transcutaneous auricular vagus nerve stimulation (taVNS), a non-invasive neuromodulation technique, holds promise as a therapeutic option by leveraging the bottom-up modulation of brain activity via the auricular branch of the vagus nerve. This study aims to evaluate the neurophysiological and clinical effects of taVNS on brain activity and symptomatology in patients with PPCS through a randomized, controlled, double-blind trial.
The 2 groups in the trial
- Active taVNSTreatment being tested
Patients will undergo 15 sessions of 30-min active taVNS applied to the cymba conchae of the left ear. Clinical assessments-including symptom severity questionnaires and neuropsychological tests-along with neurophysiological recordings (hd-EEG and electrocardiography) will be conducted on the first (S1) and final (S15) days of the intervention. The remaining 13 sessions (S2-14) will be self-administered by patients at home. To monitor safety, participants will report any side effects after each session. To monitor adherence, the device will record the time and duration of each stimulation session. Blinding efficacy will be evaluated at the end of the intervention by asking participants to indicate whether they believe they received active or sham stimulation, and to rate their confidence in that response. A follow-up assessment will occur one month after the intervention, during which symptom severity questionnaires will be administered via a phone interview.
- Sham taVNSSham treatment, for comparison
Patients will undergo 15 sessions of 30-min sham taVNS applied to the cymba conchae of the left ear. Clinical assessments-including symptom severity questionnaires and neuropsychological tests-along with neurophysiological recordings (hd-EEG and electrocardiography) will be conducted on the first (S1) and final (S15) days of the intervention. The remaining 13 sessions (S2-14) will be self-administered by patients at home. To monitor safety, participants will report any side effects after each session. To monitor adherence, the device will record the time and duration of each stimulation session. Blinding efficacy will be evaluated at the end of the intervention by asking participants to indicate whether they believe they received active or sham stimulation, and to rate their confidence in that response. A follow-up assessment will occur one month after the intervention, during which symptom severity questionnaires will be administered via a phone interview.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Effects of Transcutaneous Auricular Vagus Nerve Stimulation in Patients With Persistent Post-concussion Symptoms: a Randomized Double-blind Controlled Trial
- Criteria questions
- Built from NCT07017257, who can take part
- Record updated
- 12 June 2025